Debio-0123 [2243882-74-6]
Cat# T9864-5mg
Size : 5mg
Brand : TargetMol
Contact local distributor :
Phone : +1 850 650 7790
Debio-0123
(Synonyms: WEE1-IN-5) Copy Product Info
Debio-0123 (WEE1-IN-5) is a potent, orally available and highly specific WEE1 inhibitor with an IC 50 in the low nanomolar range. Debio-0123 inhibits phospho-CDC2 which translated into an increase in DNA damage and premature entry into mitosis. Debio-0123 increases the antitumoral activity of Carboplatin in vivo whereas neither agent was active alone [1].
Cas No. 2243882-74-6
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
For research use only—not for human use. No sales to individuals. Use as intended only.
Select Batch
Purity:99.93%
Appearance:Solid
Color:White
COA LCMS HNMR
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | Debio-0123 (WEE1-IN-5) is a potent, orally available and highly specific WEE1 inhibitor with an IC 50 in the low nanomolar range. Debio-0123 inhibits phospho-CDC2 which translated into an increase in DNA damage and premature entry into mitosis. Debio-0123 increases the antitumoral activity of Carboplatin in vivo whereas neither agent was active alone [1]. |
| In vitro | WEE1-IN-5 shows an EC 50 of 188 nM in pCDC2 and an IC 50 shift for CYP3A4/5 [1]. |
| In vivo | WEE1-IN-5, administered as a single dose of 5mg/kg orally (PO) and 1mg/kg intravenously (IV), demonstrates a clearance rate (CL) of 14 mL/min/kg, an area under the curve (AUC) of 1324 h·ng/mL, and a bioavailability of 35% in SD rats [1]. |
| Synonyms | WEE1-IN-5 |
| Molecular Weight | 511.45 |
| Formula | C26H28Cl2N6O |
| Cas No. | 2243882-74-6 |
| Smiles | CN1CCC(CC1)c1ccc(Nc2ncc3C(=O)N(CN(C)c3n2)c2c(Cl)cccc2Cl)cc1C |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 50 mg/mL (97.76 mM), Sonication and heating to 60℃ are recommended.  | ||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 1 mg/mL (1.96 mM), Sonication is recommended. 10% DMSO+90% Saline: 5 mg/mL (9.78 mM), Suspension. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density. | |||||||||||||||||||||||||||||||